Benjamin Thoreau

Dr. Benjamin Thoreau

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
GBGuillaume Bayer
Guillaume Bayer
FTFlorent von Tokarski
Florent von Tokarski
BTBenjamin Thoreau
Benjamin Thoreau
ABAdeline Bauvois
Adeline Bauvois
CBChristelle Barbet
Christelle Barbet
JHJean-Michel Halimi
Jean-Michel Halimi
Background and objectives Thrombotic microangiopathies constitute a diagnostic and therapeutic challenge. Secondary thrombotic microangiopathies are less characterized than primary thrombotic microangiopathies (thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome). The relative frequencies and outcomes of secondary and primary thrombotic microangiopathies are unknown. Design, setting, participants, & measurements We conducted a retrospective study in a four-hospital institution in 564 consecutive patients with adjudicated thrombotic microangiopathies during the 2009–2016 period. We estimated the incidence of primary and secondary thrombotic microangiopathies, thrombotic microangiopathy causes, and major outcomes during hospitalization (death, dialysis, major cardiovascular events [acute coronary syndrome and/or acute heart failure], and neurologic complications [stroke, cognitive impairment, or epilepsy]). Results We identified primary thrombotic microangiopathies in 33 of 564 patients (6%; thrombotic thrombocytopenic purpura: 18 of 564 [3%]; atypical hemolytic and uremic syndrome: 18 of 564 [3%]). Secondary thrombotic microangiopathies were found in 531 of 564 patients (94%). A cause was identified in 500 of 564 (94%): pregnancy (35%; 11 of 1000 pregnancies), malignancies (19%), infections (33%), drugs (26%), transplantations (17%), autoimmune diseases (9%), shiga toxin due to Escherichia coli (6%), and malignant hypertension (4%). In the 31 of 531 patients (6%) with other secondary thrombotic microangiopathies, 23% of patients had sickle cell disease, 10% had glucose-6-phosphate dehydrogenase deficiency, and 44% had folate deficiency. Multiple causes of thrombotic microangiopathies were more frequent in secondary than primary thrombotic microangiopathies (57% versus 19%; P<0.001), and they were mostly infections, drugs, transplantation, and malignancies. Significant differences in clinical and biologic differences were observed among thrombotic microangiopathy causes. During the hospitalization, 84 of 564 patients (15%) were treated with dialysis, 64 of 564 patients (11%) experienced major cardiovascular events, and 25 of 564 patients (4%) had neurologic complications; 58 of 564 patients (10%) died, but the rates of complications and death varied widely by the cause of thrombotic microangiopathies. Conclusions Secondary thrombotic microangiopathies represent the majority of thrombotic microangiopathies. Multiple thrombotic microangiopathies causes are present in one half of secondary thrombotic microangiopathies. The risks of dialysis, neurologic and cardiac complications, and death vary by the cause of thrombotic microangiopathies. Visual Abstract Podcast This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_03_12_CJASNPodcast_19_04_.mp3

12 September 2017 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
ABAdrien Bigot
Adrien Bigot
MTMichel C. Tchan
Michel C. Tchan
BTBenjamin Thoreau
Benjamin Thoreau
Helene BlascoHelene Blasco
Helene Blasco
FMFrancois Maillot
Francois Maillot

21 December 2023 in Autoimmunity Reviews
Verified
Journal Article
Closed access
BTBenjamin Thoreau
Benjamin Thoreau
LMLuc Mouthon
Luc Mouthon

1 March 2017 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
BTBenjamin Thoreau
Benjamin Thoreau
FGF Gouaillier-Vulcain
F Gouaillier-Vulcain
LML Machet
L Machet
CMC Mateus
C Mateus
Caroline RobertCaroline Robert
Caroline Robert
BLB Lioger
B Lioger
Is missing (SHort communication)...

27 November 2023 in Journal of Internal Medicine
Verified
Journal Article
Closed access
KCKevin Chevalier
Kevin Chevalier
BTBenjamin Thoreau
Benjamin Thoreau
MMMarc Michel
Marc Michel
BGBertrand Godeau
Bertrand Godeau
CAChristian Agard
Christian Agard
LMLuc Mouthon
Luc Mouthon

26 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
BTBenjamin Thoreau
Benjamin Thoreau
JGJoris Galland
Joris Galland
MDMaxime DELRUE
Maxime DELRUE
MNMarie Neuwirth
Marie Neuwirth
ASAlain Stépanian
Alain Stépanian
DSDamien Sene
Damien Sene
The incidence of pulmonary embolism (PE) is high during severe Coronavirus Disease 2019 (COVID-19). We aimed to identify predictive and prognostic factors of PE in non-ICU hospitalized COVID-19 patients. In the retrospective multicenter observational CLOTVID cohort, we enrolled patients with confirmed RT-PCR COVID-19 who were hospitalized in a medicine ward and also underwent a CT pulmonary angiography for a PE suspicion. Baseline data, laboratory biomarkers, treatments, and outcomes were collected. Predictive and prognostics factors of PE were identified by using logistic multivariate and by Cox regression models, respectively. A total of 174 patients were enrolled, among whom 86 (median [IQR] age of 66 years [55–77]) had post-admission PE suspicion, with 30/86 (34.9%) PE being confirmed. PE occurrence was independently associated with the lack of long-term anticoagulation or thromboprophylaxis (OR [95%CI], 72.3 [3.6–4384.8]) D-dimers ≥ 2000 ng/mL (26.3 [4.1–537.8]) and neutrophils ≥ 7.0 G/L (5.8 [1.4–29.5]). The presence of these two biomarkers was associated with a higher risk of PE (p = 0.0002) and death or ICU transfer (HR [95%CI], 12.9 [2.5–67.8], p < 0.01). In hospitalized non-ICU severe COVID-19 patients with clinical PE suspicion, the lack of anticoagulation, D-dimers ≥ 2000 ng/mL, neutrophils ≥ 7.0 G/L, and these two biomarkers combined might be useful predictive markers of PE and prognosis, respectively.